|| Home | Market Analysis | International Investor |
| Online Share Selection | Free Advice | About Us |
| Subscribe to Our Services | Access Your Account |
This Summary prepared: January 2020
"Market Analysis" has been published since
1981, this Summary is split by decades -
|Buy Recommendation||Sell Recommendation||Dividends||Recent||%|
Our portfolio gains just 4.2% for the year - at least outperforming the market. We bought Ammtec for long term growth in January, but it was taken over by Campbell Brothers, realising a 73% gain. Finbar Group and CSG were bought for growth and Nomad Building Solutions as a recovery situation.
|~Onterran (Nomad Buildings)||16-08-10||103*||08-08-19||Nil||Nil||-100|
Our portfolio dips 6.5% in value. Markets remain volatile. We buy Customers (as an undervalued situation - but it is taken over a year later), Novarise for growth and Penrice Soda as a high risk recovery situation.
The markets remain volatile - with a big dip in the June quarter - but ends the year ahead. Many of our shares are volatile, with a mix of gains and losses for the year, but overall the portfolio manages a very good 24.2% gain.
For the year, TFS Corporation is up 199% and Prophecy up 127%, lifting our portfolio to an excellent 21.5% gain.
|~CardieX Ltd (AtCor Medical)||11-11-13||15||Nil||7.2||-52|
The portfolio dips 9.8%.
|~Mt Gibson Iron||10-11-14||44||12.0||98||+150|
The ASX index fell -8.4% but our portfolio rose +29.5%. Technology One and Prophecy International became 10-baggers in November 2015 (but Prophecy fell back slightly at year end). Prophecy ended up +278.8% for the year, Opthea (Circadian) up +212.9% and Ellex Medical up +172.7%. We made no new buys or sells (except Chandler Macleod was taken over) as we are happy with the portfolio, so why change it?
Our portfolio rises +14.9%, the ASX +14.6%. M2 Telecommunications merges with Vocus Communications in January and in August we sell to realise a 47-fold gain over 10 years.
|~Reckon Limited (+1/3 GETB)||08-08-16||141||15.0||128||+2|
Our portfolio rises just +5.5%.
Cynata Therapuetics doubles, but Noverise and Quintis are written-off. The portfolio falls -23.6%.
Opthea Ltd rises strongly, but Onterran is written-off. The portfolio gains +15.6%.
* Recommendation Prices Adjusted for Splits, Bonus and Cash Issues.
© 1997-2021 Securities Research Company Limited.